NDLI: Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.

Please wait, while we are loading the content...

Impact of a rapid multiplex polymerase chain reaction blood culture identification technology on outcomes in patients with vancomycin-resistant Enterococcal bacteremia.

Stenotrophomonas maltophilia ventilator-associated pneumonia. A retrospective matched case-control study.

Best oral empirical treatment for pyelonephritis in children: Do we need to differentiate between age and gender?

Epidemiological and clinical characteristics of Shewanella spp. infections in a tertiary hospital in Madrid.

Sinus aspergillosis due to an azole-resistant Aspergillus fumigatus strain carrying the TR34/L98H mutation in immunocompetent host.

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.

Pulmonary M. scrofulaceum disease showing false-positive response of anti-GPL core IgA antibody.

No serological evidence for Borrelia burgdorferi sensu lato infection in patients with dilated cardiomyopathy in Northern France.

Molecular events by which dendritic cells promote Th2 immune protection in helmith infection.

Use of 18F-FDG PET/CT for diagnosis of vascular graft infection with spread to sternum caused by Coxiella burnetii.

Site of infection and mortality in patients with severe sepsis or septic shock. A cohort study of patients admitted to a Danish general intensive care unit.

Treatment efficacy of Ampicillin/Sulbactam in comparison to alternative beta-lactams for severe Acinetobacter baumannii infections.

Optimizing the virological success of tenofovir DF/FTC/rilpivirine in HIV-infected naive and virologically suppressed patients through strict clinical and virological selection.

Microbiological contamination of the euro currency in Estonia.

Year: 2016 Volume: 48 Issue: 9

Year: 2016 Volume: 48 Issue: 8

Year: 2016 Volume: 48 Issue: 7

Year: 2016 Volume: 48 Issue: 6

Year: 2016 Volume: 48 Issue: 5

Year: 2016 Volume: 48 Issue: 3

Year: 2016 Volume: 48 Issue: 2

Year: 2016 Volume: 48 Issue: 1

Year: 2016 Volume: 48 Issue: 11-12

Year: 2015 Volume: 47

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Syrogiannopoulos, George A. Michoula, Aspasia N. Tsimitselis, Georgios Vassiou, Katerina Chryssanthopoulou, Denise C. Grivea, Ioanna N.
Description	Author Affiliation: Syrogiannopoulos GA ( a Department of Paediatrics , University of Thessaly, School of Health Sciences, Faculty of Medicine , Larissa , Greece ); Michoula AN ( a Department of Paediatrics , University of Thessaly, School of Health Sciences, Faculty of Medicine , Larissa , Greece ); Tsimitselis G ( b Department of Radiology , University of Thessaly, School of Health Sciences, Faculty of Medicine , Larissa , Greece ); Vassiou K ( b Department of Radiology , University of Thessaly, School of Health Sciences, Faculty of Medicine , Larissa , Greece ); Chryssanthopoulou DC ( c Department of Anatomy , University of Thessaly, School of Health Sciences, Faculty of Medicine , Larissa , Greece.); Grivea IN ( a Department of Paediatrics , University of Thessaly, School of Health Sciences, Faculty of Medicine , Larissa , Greece )
Abstract	BACKGROUND: Parapneumonic effusions in children are usually associated with pneumococcal infections. In Greece, the 7-valent pneumococcal conjugate vaccine was replaced by higher-valent pneumococcal conjugate vaccines (PCVs); 10-valent was introduced in May 2009 and 13-valent (PCV13) in June 2010. Since July 2010, PCV13 has been the most commonly used PCV. In a study conducted at the University General Hospital of Larissa, Central Greece, from January 2012 to January 2016, 85.7% of children born after the implementation of PCV13 and aged 24-59 months had received the complete series (3 + 1 immunization schedule) of PCV13. METHODS: We studied all paediatric community-acquired pneumonia cases with empyema hospitalized at the University General Hospital of Larissa from January 2008 to January 2016. RESULTS: There were 30 cases of parapneumonic empyema. Among 27 empyema cases of known aetiology, 19 (70.4%) were due to Streptococcus pneumoniae (identifiable serotypes 3, 19A, 7F, and 9N/L). After September 2011, no more cases caused by serotypes 7F and 19A were observed, whereas serotype 3 emerged as the predominant pathogen of pneumococcal empyema (9 of 11 cases). Serotype 3 continued to cause empyema despite vaccination with PCV13 either fully with a 3 + 1 schedule (n = 3) or with one booster dose at the age of 21 months (n = 1). CONCLUSION: In Central Greece during the first five years of high coverage with PCV13, serotype 3 was the only PCV13 serotype that clearly persisted in children with empyema.
File Format	HTM / HTML
ISSN	23744235
Issue Number	10
Journal	Infectious Diseases
Volume Number	48
e-ISSN	23744243
Language	English
Publisher	Taylor & Francis
Publisher Date	2016-10-01
Publisher Place	Great Britain (UK)
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Communicable Diseases
Content Type	Text
Resource Type	Article
Subject	Infectious Diseases Immunology and Microbiology Microbiology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years—Zimbabwe, 2010–2016

Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era

Effect of 10-valent pneumococcal conjugate vaccine on trends of pneumococcal meningitis in children under five years, Uganda, 2003–2022

Invasive Pneumococcal Disease and 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Coverage Among Children Aged ≤59 Months—Selected U.S. Regions, 2010-2011

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan

Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era

12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults

2717. The Impact of Pneumococcal Conjugate Vaccine in Nonbacteremic Pneumococcal Pneumonia Among Cancer Patients

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.

Similar Documents

Pneumococcal Conjugate Vaccine Impact on Meningitis and Pneumonia Among Children Aged <5 Years—Zimbabwe, 2010–2016

Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era

Effect of 10-valent pneumococcal conjugate vaccine on trends of pneumococcal meningitis in children under five years, Uganda, 2003–2022

Invasive Pneumococcal Disease and 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Coverage Among Children Aged ≤59 Months—Selected U.S. Regions, 2010-2011

Decrease of Pneumococcal Community-Acquired Pneumonia Hospitalization and Associated Complications in Children after the Implementation of the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) in Taiwan

Pneumococcal Pneumonia Requiring Hospitalization in US Children in the 13-Valent Pneumococcal Conjugate Vaccine Era

12 years active surveillance for pediatric pleural empyema in a Mexican hospital: effectiveness of pneumococcal 13-valent conjugate vaccine, and early emergence of methicillin-resistant Staphylococcus aureus

Expanded Analysis of 20 Pneumococcal Serotypes Associated With Radiographically Confirmed Community-acquired Pneumonia in Hospitalized US Adults

2717. The Impact of Pneumococcal Conjugate Vaccine in Nonbacteremic Pneumococcal Pneumonia Among Cancer Patients

Pneumonia with empyema among children in the first five years of high coverage with 13-valent pneumococcal conjugate vaccine.